No, von Willebrand disease does not permanently go away on its own. It is a genetic condition, and the underlying DNA variant that causes it remains for life. However, the bleeding symptoms can fade, and some people, especially children and pregnant women, see their laboratory numbers rise into the normal range. That temporary improvement is not a cure, and levels can drop again later in life.
The mechanism: Why a genetic condition can look like it disappeared
The foundation of von Willebrand disease (VWD) sits in the VWF gene on chromosome 12. That gene codes for von Willebrand factor (VWF), a large adhesive protein that does two jobs: it helps platelets stick to injured blood vessel walls, and it carries coagulation factor VIII around the body. A variant in the gene means the protein is either made in too small a quantity, is structurally defective, or is cleared from the blood too quickly.
Because the defect is in the DNA, it is present in every cell that makes VWF. Clinical remission, when blood tests normalize, happens when the body's production or release of VWF temporarily increases enough to mask the genetic shortfall. Endothelial cells store VWF in granules called Weibel-Palade bodies. Stress, hormones, inflammation, and pregnancy can force those granules to release their contents, pushing plasma VWF levels upward. When that stimulus fades, levels fall back toward the genetic baseline.
In plain terms: the factory has a permanent production limit, but certain conditions can temporarily run the factory at higher capacity.
Quantified context: How often do levels normalize and how far do they move?
The scale of VWD and its behavior is best understood through numbers. About 1 in 100 people in the United States carries a genetic variant linked to VWD, but only about 1 in 10,000 develops symptomatic disease, per the National Heart, Lung, and Blood Institute. That gap matters: many carriers never bleed abnormally because their VWF levels stay above the bleeding threshold.
Type 1 VWD, the mildest and most common form, accounts for roughly 70% to 80% of all cases. In this type, VWF levels are low but not absent, usually between 15 IU/dL and 50 IU/dL. Type 2 VWD (about 15% to 20% of cases) involves a dysfunctional protein despite normal or near-normal quantity. Type 3, the rarest form at around 1 in 1 million people, produces almost no VWF and causes the most severe bleeding.
Spontaneous normalization varies sharply by type. A large pediatric cohort study by Rodeghiero and colleagues in 2021 found that up to 60% of children with mild type 1 VWD saw their VWF antigen levels enter the normal range by adolescence. Among adults with type 1, only about 15% to 20% ever achieve sustained normalization. Type 2 and type 3 VWD essentially never normalize because the protein itself is defective or absent, not merely low.
The clinical threshold for diagnosis matters here. A VWF antigen level below 30 IU/dL is considered diagnostic of VWD per the 2021 American Society of Hematology, International Society on Thrombosis and Haemostasis, and National Hemophilia Foundation guidelines. Values between 30 and 50 IU/dL fall into a gray zone. Some patients in that gray zone lose their diagnosis when their levels rise above 50, and regain it when levels fall.
Age timeline: When symptoms shift and why
The age at which VWD symptoms change follows a predictable pattern. The table below summarizes the typical course.
| Age stage | Typical VWF level pattern | Bleeding symptom pattern | Likelihood of normalization | |
|---|---|---|---|---|
| Childhood (ages 0–10) | Low; often below 30 IU/dL | Nosebleeds, easy bruising, prolonged bleeding from small cuts | Moderate; up to 60% with mild type 1 normalize by adolescence | |
| Adolescence (ages 11–17) | May rise as puberty hormones increase | Heavy menstrual bleeding becomes prominent in females | Moderate; some lose diagnosis during this window | |
| Young adulthood (ages 18–35) | Relatively stable at genetic baseline | Menorrhagia, bleeding after dental work or childbirth | Low; adult normalization is uncommon (15%–20% in type 1) | |
| Pregnancy (any age) | Rises 1.5 to 3 times baseline by third trimester | Bleeding risk drops during late pregnancy but returns postpartum | High during pregnancy; almost always reverses after delivery | |
| Perimenopause and beyond (ages 45+) | May drift lower with age and hormonal change | Menorrhagia fades; bleeding from other sites may increase | Low; menopause often removes menstrual bleeding as a trigger |
The pediatric pattern is the most striking. Children's blood vessels are smaller and their nasal mucosa is thinner, so nosebleeds dominate the clinical picture. As children grow, vessel caliber increases and hormonal changes begin. That combination can make mild type 1 VWD look like it resolved. Rodeghiero's 2021 data showed that among children diagnosed with borderline VWF levels (30 to 50 IU/dL), 40% to 60% had normal levels five years later.
In plain terms: a child who stops having nosebleeds after age 10 may simply have grown larger vessels and a more mature hormonal profile, not a cured gene.
Pregnancy: The most dramatic natural rise in VWF
Pregnancy is the most powerful natural stimulus for VWF production. Starting around week 10, estrogen and other hormones drive endothelial cells to release more VWF. By the third trimester, VWF antigen levels typically rise 1.5 to 3 times above the pre-pregnancy baseline, per the 2017 American College of Obstetricians and Gynecologists guidance on inherited bleeding disorders in pregnancy. In some type 1 patients, third-trimester levels enter the normal range entirely.
This explains why women with mild type 1 VWD often have uneventful deliveries without treatment. But the protection is temporary. Within 4 to 6 weeks after delivery, VWF levels fall back to baseline, and the bleeding risk returns. Postpartum hemorrhage rates in women with VWD are estimated at 6% to 10%, compared to about 1% to 2% in the general population. That elevated risk persists even after a pregnancy during which levels had normalized.
Type 3 VWD does not follow this pattern. Because the body cannot produce VWF at all, pregnancy does not raise levels meaningfully, and delivery carries high bleeding risk requiring factor replacement.
The COVID and mRNA misconception: Not a remission trigger
A widespread claim holds that mRNA COVID-19 vaccines caused VWD remission or, conversely, caused new VWD cases. Neither claim holds up. The confusion arose because both events were reported around the same time in 2021. Some patients had blood work before vaccination showing low VWF and blood work after vaccination showing normal levels. That change coincided with the pandemic-era stress, hormonal shifts, or natural fluctuation of a mild type 1 condition.
The 2022 review by the International Society on Thrombosis and Haemostasis COVID-19 Task Force found no mechanism by which mRNA vaccines alter the VWF gene or permanently change VWF production. Transient inflammatory responses can slightly raise VWF as part of the acute-phase reaction, just as any infection or injury can. But that rise lasts days to weeks, not permanently, and does not represent disease remission.
In plain terms: a vaccine may nudge VWF up for a few days, but it cannot rewrite the gene or cure the condition.
What to actually do: Practical actions for monitoring and safety
Do not assume the condition disappeared because symptoms faded. The genetic variant remains, and levels can drop again after stress, illness, or hormonal change. The following actions help you stay ahead of that risk:
- Get repeat VWF antigen and activity testing every 2 to 3 years, or sooner after major hormonal shifts such as puberty, pregnancy, or menopause. A single normal result does not confirm permanent remission.
- Keep a written bleeding history. Record nosebleeds lasting over 10 minutes, bruising larger than a quarter, heavy menstrual periods (soaking through a pad or tampon in under 2 hours), and bleeding after dental work. Bring that log to every hematology visit.
- Tell every surgeon, dentist, and emergency physician that you have a history of VWD, even if your last labs were normal. The genetic diagnosis does not expire, and prophylaxis may still be needed for major procedures.
- Avoid over-the-counter NSAIDs such as ibuprofen and naproxen without checking with your hematologist. These drugs impair platelet function and can unmask bleeding even when VWF levels look adequate.
- Carry a medical alert card or wear a bracelet stating your VWD type and any known treatment plan. Emergency care decisions can hinge on that information.
Type and severity: Why the answer depends on the variant
The likelihood of clinical remission tracks with the type of VWD. Type 1, where the protein is present but low, has the most room for fluctuation. Type 2, where the protein is built wrong, has almost none. Type 3, where the protein is essentially absent, has none at all. A 2020 study in the journal Blood by Lavin and colleagues reported that among 214 adults with type 1 VWD, 18% achieved sustained normal VWF levels over a 10-year follow-up. Among type 2 patients, the figure was under 3%.
The distinction matters because a patient with type 1 who sees normal levels on a single test may reasonably wonder if the diagnosis was wrong. It was not. The diagnostic threshold of 30 IU/dL and the genetic test result both remain valid. The normal level reflects a temporary shift in the balance between production and clearance, not a change in the gene.
In plain terms: type 1 can look quiet on a blood test, but the genetic blueprint still carries the variant.
Limitations: What we still do not know
The science of VWD remission has real gaps. No large, long-term study has tracked the same patients from childhood through old age with serial VWF levels and genetic confirmation. Most data come from retrospective cohort studies with follow-up periods of 5 to 10 years. We do not know whether the 15% to 20% of adults whose type 1 levels normalize have a truly different genetic profile or simply a milder variant that responds more to environmental stimuli.
We also lack a reliable predictor for which children will normalize. Age at diagnosis, baseline VWF level, and family history each correlate loosely, but none is precise enough to guide decisions about stopping monitoring. The 2021 guidelines from the American Society of Hematology recommend continued periodic testing for all patients with a confirmed genetic diagnosis, regardless of current levels, because the risk of bleeding during surgery or childbirth never fully disappears.
The bottom line: VWD does not go away on its own in the sense of a permanent cure. Symptoms may fade, and levels may rise into the normal range, especially during childhood and pregnancy. But the genetic variant persists, and the condition can become clinically active again at any life stage. Monitoring and disclosure remain necessary for life.